Dr Barbara Lipert
I am a cellular and molecular biologist, with a particular interest in the clinical application of CRISPR technology. I obtained a PhD in Biochemistry at the Jagiellonian University in Krakow, Poland (2016) where I studied a newly discovered gene in the context of carcinogenesis and cell differentiation (adipogenesis). In 2017, I joined the Auckland Cancer Society Research Centre (ACSRC) where I apply CRISPR technologies in functional genomics studies.
Research | Current
1. DNA repair mechanisms in cancer cells - exploiting weaknesses to improve treatment
2. Identification of the biomarkers for precision oncology:
- CRISPR knock-out genetic screens for the whole-genome interrogation of genetic dependencies to anticancer therapies - chemotherapy, radiotherapy and antibody-drug conjugate T-DM1 (Kadcyla®)
- Generating knock-in and knock-out model cell lines for validation studies
Co-supervisor of Masters Project: Identification of genes that confer tolerance to tumour microenvironmental stress using CRISPR-Cas9 screens. Ms Hanting Yong, 2019.
Co-supervisor of Honours Project: In Pursuit of Precision: Determinants of sensitivity and resistance to the drug trastuzumab emtansine for HER2-positive breast cancer. Ms Hilary Barker, 2018.
Supervisor of the Summer Student Projects in 2019-2021.
Selected publications and creative works (Research Outputs)
- Hunter, F. W., Barker, H. R., Lipert, B., Rothé F, Gebhart, G., Piccart-Gebhart, M. J., ... Jamieson, S. M. F. (2020). Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. British journal of cancer, 122 (5), 603-612. 10.1038/s41416-019-0635-y
Other University of Auckland co-authors: Stephen Jamieson, Francis Hunter
- Lee, T. W., Wong, W. W., Dickson, B. D., Lipert, B., Cheng, G. J., Hunter, F. W., ... Wilson, W. R. (2019). Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International journal of radiation biology, 95 (12), 1597-1612. 10.1080/09553002.2019.1664787
Other University of Auckland co-authors: Francis Hunter, Benjamin Dickson, Michael Hay, Way Wong
- Wong, W. W., Jackson, R. K., Liew, L. P., Dickson, B. D., Cheng, G. J., Lipert, B., ... Hay, M. P. (2019). Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical pharmacology, 16910.1016/j.bcp.2019.113641
Other University of Auckland co-authors: Way Wong, Benjamin Dickson, Yongchuan Gu, Francis Hunter, Michael Hay, Lydia Liew
- Ligeza, J., Marona, P., Gach, N., Lipert, B., Miekus, K., Wilk, W., ... Dulak, J. (2017). MCPIP₁ contributes to clear cell renal cell carcinomas development. Angiogenesis, 20 (3), 325-340. 10.1007/s10456-017-9540-2
- Lipert, B., Wilamowski, M., Gorecki, A., & Jura, J. (2017). MCPIP1, alias Regnase-1 binds and cleaves mRNA of C/EBPβ. PloS one, 12 (3)10.1371/journal.pone.0174381
- Ruiz-Romeu, E., Ferran, M., Giménez-Arnau A, Bugara, B., Lipert, B., Jura, J., ... Pujol, R. M. (2016). MCPIP1 RNase is aberrantly distributed in psoriatic epidermis and rapidly induced by IL-17A. Journal of Investigative Dermatology, 136 (8), 1599-1607. 10.1016/j.jid.2016.04.030
- Lipert, B. (2016). Rola MCPIP1 w różnicowaniu preadipocytów (Determining the role of MCPIP1 ribonuclease in adipogenesis) The Jagiellonian University, Krakow, Poland. The Jagiellonian University, Krakow, Poland.
- Labedz-Maslowska, A., Lipert, B., Berdecka, D., Kedracka-Krok, S., Jankowska, U., Kamycka, E., ... Jura, J. (2015). Monocyte chemoattractant protein-induced protein 1 (MCPIP1) enhances angiogenic and cardiomyogenic potential of murine bone marrow-derived mesenchymal stem cells. PloS ONE, 10 (7)10.1371/journal.pone.0133746